JP2012504604A5 - - Google Patents

Download PDF

Info

Publication number
JP2012504604A5
JP2012504604A5 JP2011530048A JP2011530048A JP2012504604A5 JP 2012504604 A5 JP2012504604 A5 JP 2012504604A5 JP 2011530048 A JP2011530048 A JP 2011530048A JP 2011530048 A JP2011530048 A JP 2011530048A JP 2012504604 A5 JP2012504604 A5 JP 2012504604A5
Authority
JP
Japan
Prior art keywords
alkyl
alkenyl
alkynyl
con
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011530048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504604A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/005407 external-priority patent/WO2010039237A1/en
Publication of JP2012504604A publication Critical patent/JP2012504604A/ja
Publication of JP2012504604A5 publication Critical patent/JP2012504604A5/ja
Pending legal-status Critical Current

Links

JP2011530048A 2008-10-01 2009-10-01 炎症および免疫関連使用のための化合物 Pending JP2012504604A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19483108P 2008-10-01 2008-10-01
US61/194,831 2008-10-01
PCT/US2009/005407 WO2010039237A1 (en) 2008-10-01 2009-10-01 Compounds for inflammation and immune-related uses

Publications (2)

Publication Number Publication Date
JP2012504604A JP2012504604A (ja) 2012-02-23
JP2012504604A5 true JP2012504604A5 (enExample) 2012-11-22

Family

ID=41263687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011530048A Pending JP2012504604A (ja) 2008-10-01 2009-10-01 炎症および免疫関連使用のための化合物

Country Status (7)

Country Link
US (3) US8314130B2 (enExample)
EP (1) EP2350064A1 (enExample)
JP (1) JP2012504604A (enExample)
AU (1) AU2009300317A1 (enExample)
CA (1) CA2739322A1 (enExample)
TW (1) TW201026693A (enExample)
WO (1) WO2010039237A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
WO2010085581A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
EP2389377B1 (en) 2009-01-23 2014-07-16 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP6112486B2 (ja) 2010-04-27 2017-04-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
EP2563759B1 (en) 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN103180316A (zh) 2010-08-27 2013-06-26 钙医学公司 调节细胞内钙的化合物
PL2668182T3 (pl) * 2011-01-28 2018-11-30 Immunic Ag Inhibitowanie IL17 i IFN-gamma do leczenia zapalenia autoimmunologicznego
EP2704701B1 (en) * 2011-05-03 2018-01-03 PRCL Research Inc. Compounds for inflammation and immune-related uses
WO2012170931A2 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
TWI771269B (zh) 2015-02-27 2022-07-21 美商鈣系醫藥公司 胰腺炎治療
CA2995094A1 (en) 2015-08-07 2017-02-16 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
WO2019054430A1 (ja) * 2017-09-14 2019-03-21 第一三共株式会社 芳香族複素環を有するアミド化合物
JP2022508468A (ja) 2018-09-14 2022-01-19 ルヒゼン ファーマスティカルズ アクツィエンゲゼルシャフト Ｃｒａｃ阻害剤およびコルチコステロイドを含む組成物ならびにそれらの使用方法
US12486274B2 (en) 2020-01-13 2025-12-02 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
CA3172249A1 (en) 2020-03-20 2021-09-23 Calcimedica, Inc. Methods and compositions for treating acute lung injury and acute respiratory distress syndrome
JP7791898B2 (ja) 2020-11-13 2025-12-24 カルシメディカ，インク． Ｃｒａｃチャネル阻害剤の合成の改善
CN118084860A (zh) * 2024-02-06 2024-05-28 中国药科大学 芳酰胺类化合物及其药物组合物和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6451820B1 (en) * 2000-03-23 2002-09-17 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents
HUP0401748A3 (en) * 2001-08-13 2011-03-28 Janssen Pharmaceutica Nv 2-amino-4,5-trisubstituted thiazolyl derivatives, process for their preparation and pharmaceutical compositions containing them
HRP20040098B1 (en) * 2001-08-13 2012-08-31 Janssen Pharmaceutica N.V. 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY
WO2006083477A2 (en) * 2005-01-07 2006-08-10 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2006081389A1 (en) * 2005-01-25 2006-08-03 Synta Pharmaceuticals Corp. Thiophene compounds for inflammation and immune-related uses
CA2639913A1 (en) * 2006-01-25 2007-08-02 Synta Pharmaceutical Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
ES2440267T3 (es) 2007-08-01 2014-01-28 Synta Pharmaceuticals Corporation Compuestos de heterociclo-arilo para la inflamación y usos inmunorrelacionados
TW200911800A (en) 2007-08-01 2009-03-16 Synta Pharmaceuticals Corp Pyridine compounds for inflammation and immune-related uses

Similar Documents

Publication Publication Date Title
JP2012504605A5 (enExample)
JP2010509342A5 (enExample)
CA2669695A1 (en) Tetrahydropyridinyl compounds for inflammation and immune-related uses
JP2012504603A5 (enExample)
JP2010535218A5 (enExample)
JP2011525915A5 (enExample)
JP2010519206A5 (enExample)
JP2019163290A5 (enExample)
AU2008287799B2 (en) Method for producing pyripyropene derivative and production intermediate thereof
AU2019260159B2 (en) HPK1 inhibitors, preparation method and application thereof
JP2013525433A5 (enExample)
JP2010535214A5 (enExample)
NZ603427A (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
WO2017218580A1 (en) Synthetic methods for the preparation of nicotinamide riboside and related compounds
CA2796872A1 (en) Novel synthesis for thiazolidinedione compounds
JP2009530283A5 (enExample)
JP2013533883A5 (enExample)
WO2005105732A8 (en) Substituted methyl aryl or heteroaryl amide compounds
JP2007530598A5 (enExample)
HRP20211151T1 (hr) Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama
US20190202834A1 (en) Baricitinib intermediate, method for forming baricitinib intermediate, and method for preparing baricitinib or pharmaceutically acceptable salt thereof
CN108341820B (zh) Jak酶抑制剂及其制备方法和用途
JP2015516968A5 (enExample)
JP2018502083A5 (enExample)
JP2025526425A (ja) 抗体薬物複合体に適した毒素分子